TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline

$158M Series B-2 Financing led by Deep Track Capital, with new participation from leading global biotechnology investors including RA Capital Management,...

Related Keywords

Dave Licata ,Vince Ruiz ,Ribociclib Kisqali ,Mark Alles ,Palbociclib Ibrance ,Dennis Slamon ,Perceptive Xontogeny Venture Fund ,Slamon Research Laboratory ,Bristol Myers Squibb ,Division Of Hematology Oncology ,Roth Zabel ,Crandon Law ,David Geffen School Of Medicine ,Deep Track Capital ,Perceptive Advisors ,Avidity Partners ,Goldman Sachs Alternatives ,Vertex Ventures ,Moore Strategic Ventures ,Blue Owl Healthcare Opportunities ,Notch Ligand ,Rebecca Luse ,Deep Track ,Board Member ,Scientific Co Founder Dennis Slamon ,Geffen School ,Torl Biotherapeutics Llc ,Health Care Amp Hospitals ,Biotechnology ,Venture Capital ,